Insider trade

Regeneron Pharmaceuticals (REGN): EVP Commercial sold ~$984K

Marion Mccourt, EVP Commercial at Regeneron Pharmaceuticals, sold ~$984K of Regeneron Pharmaceuticals shares.

~$984K
Approx. value · 1,132 sh @ $869.43
11K
Holds after · shares reported
Traded
Oct 30, 2026
Filed
Nov 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 2, 2026Insider · 2 peopleInsiders: 2 sales (~$1.4M)
  2. Sep 3, 2026InsiderOfficer sold ~$970K of REGN shares in the open market
  3. Sep 23, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Hopkinson v. Regeneron Pharmaceuticals, Inc.
  4. Sep 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated…”
  5. Oct 1, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
  6. Oct 1, 2026Government · Federal Register noticeAdvisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
  7. Oct 14, 2026Insider · 1 personInsiders: 27 sales (~$3.2M)
  8. Oct 30, 2026 · this disclosureInsiderOfficer sold ~$984K of REGN shares in the open market

What came next

  1. Oct 30, 2026Company filing · Form 8-K · ResultsReported its results
  2. Oct 30, 2026Insider · 2 peopleInsiders: 2 sales (~$2.0M)
  3. Nov 2, 2026Insider · 3 peopleInsiders: 17 sales (~$32.3M)
  4. Nov 3, 2026Insider · 1 personInsiders: 2 sales (~$7.2M)
  5. Nov 4, 2026Insider · 1 personInsiders: 8 sales (~$3.8M)
  6. Nov 16, 2026Insider · 1 personInsiders: 13 sales (~$544K)
  7. Nov 17, 2026Insider · 1 personInsiders: 7 sales (~$2.4M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 110 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Marion Mccourt, EVP Commercial

The full history of Marion Mccourt, EVP Commercial is on the profile page.

How this filing works

Explore the data

Common questions

Which Regeneron Pharmaceuticals (REGN) insider traded, and how much?

Marion Mccourt, EVP Commercial at Regeneron Pharmaceuticals, sold ~$984K of Regeneron Pharmaceuticals shares. 1,132 shares at $869.43.

When did it happen, and when was it made public?

Traded: Oct 30, 2026. Filed: Nov 3, 2026. That is 4 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Regeneron Pharmaceuticals recently?

For Regeneron Pharmaceuticals, OQRO holds 110 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the REGN page.

Does this mean REGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data